This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glicoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study Blood 1999 94: 1086–1099
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F . Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy Blood 1997 90: 1014–1021
Michieli M, Damiani D, Ermacora A, Masolini P, Michelutti A, Michelutti T, Russo D, Pea F, Baccarani M . Liposome-encapsulated daunorubicin for Pgp-related multidrug resistance Br J Haematol 1999 106: 92–99
Ermacora A, Michieli M, Pea F, Visani G, Bucalossi A, Russo D . Liposome encapsulated daunorubicin (DaunoXome) for acute leukemia Haematologica 2000 85: 324–325
Lippens RJJ . Liposomal daunorubicin (Daunoxome) in children with recurrent or progressive brain tumors Ped Hematol Oncology 1999 16: 131–139
Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H . High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukaemia Cancer 2001 92: 7–14
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Piccaluga, P., Visani, G., Martinelli, G. et al. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia. Leukemia 16, 1880–1881 (2002). https://doi.org/10.1038/sj.leu.2402617
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402617